Table 7.
Summary of studies with IL-6 receptor (tocilizumab) or JAK2 (ruxolitinib) blockade in treatment of chronic and acute steroid-refractory GVHD.
| Reference | Patients (n) | aGVHD (n) | cGVHD (n) | Organ involvement (patients) |
Response aGVHD | Response cGVHD | ||
|---|---|---|---|---|---|---|---|---|
| Skin | Gastrointestinal | Liver | ||||||
| Tocilizumab | ||||||||
| Drobyski et al. (161) | 8 | 6 | 2 | Grade II: 3 | Grade II: 1 | Grade III: 1 | CR 2, PR 2, NR1, NR 1 | 1 Stabilization 1 PR |
| Grade IV: 1 | Grade III: 4 | |||||||
| Roddy et al. (160) | 9 | 9 | 0 | Grade II: 1 | Grade I: 1 | Grade I: 1 | CR: 2, CR in single organ system 2 | N/A |
| Grade II: 2 | Grade II: 2 | |||||||
| Grade III: 2 | Grade III: 1 | |||||||
| Grade IV: 4 | Grade IV: 2 | |||||||
| Ganetsky et al. (159) | 5 | 5 | All patients Glücksberg grade IV | CR 5 | N/A | |||
| Ruxolitinib | ||||||||
| Zeiser et al. (122) | 95 | 54 | 41 | All patients with aGVHD grade III/IV, not otherwise specified | ORR 44, CR 25 | 35 | ||
| Spoerl et al. (121) | 6 | 4 | 2 | Grade III: 2, Grade IV: 1 | Grade IV: 2 | Grade III: 1 | CR 1, PR 3 | 2 |
CR, complete response; PR, partial response; NR, non-response; ORR, overall response rate; N/A, not applicable; GVHD, graft-versus-host disease; aGVHD, acute GVHD.